Navigating the Stormy Seas: Mixed Fortunes in the ASX Healthcare Sector
The Australian share market’s healthcare sector has navigated a turbulent reporting season, with mixed results painting a picture of both resilience and ongoing challenges. While the broader ASX Health Care Index (ASX:XHJ) saw a modest dip of 0.73% over the past week, the landscape reveals individual companies shining through the clouds, while others grapple with margin pressures.
At a broader market level, the ASX 200 (ASX:XJO) managed a slight uptick of 0.41% in the same period. This comes after a particularly grim previous week for healthcare, which endured a significant 12% fall, largely weighed down by its largest constituent, CSL (ASX:CSL). The blood and vaccine products giant had hit an eight-year low, a stark contrast to its peak in early 2020. However, CSL has shown signs of recovery this week, securing a US$100 million licensing deal with Eli Lilly for its anti-interleukin-6 monoclonal antibody, clazakizumab, with the potential for further milestone and royalty payments. Despite this positive development, regaining investor confidence remains a key objective for CSL, with a strong second-half performance anticipated to meet guidance.
Scott Power, a seasoned healthcare and life sciences expert with 27 years at Morgans Financial, highlights the standout performers amidst the sector’s reporting season. He points to pathology and radiology provider Sonic Healthcare (ASX:SHL), protective gear manufacturer Ansell (ASX:ANN), and radiopharmaceuticals company Telix Pharmaceuticals (ASX:TLX) as the “little rays of sunshine” that have offered much-needed relief.
Sonic Healthcare Soars on Stronger-Than-Expected Results
Sonic Healthcare emerged as a significant winner this week, experiencing a share price surge of approximately 13% following the release of its first-half financial results. The company exceeded market expectations, reporting an 11% increase in net profit to $262 million. Revenue also climbed 17% to $5,445 million, coming in 2–3% ahead of market forecasts.
Morgans healthcare analyst Derek Jellinek noted that underlying EBITDA of $907 million, up 10%, was largely in line with consensus, with adjusted margins expanding by 30 basis points to 18.1%. This expansion demonstrates effective operating leverage and the realisation of synergies. A key positive surprise was organic revenue growth of 5%, outpacing the market’s expectation of 3-4%.
Crucially, Sonic maintained its full-year FY26 constant currency EBITDA guidance of $1.87-$1.95 billion, an 8-13% increase, which Jellinek deemed “achievable”. The company declared an interim dividend of 45 cents, a 2.3% increase. While the US remains Sonic’s weakest region, impacted by low growth and restructuring costs, an operational review is underway to rationalise anatomical pathology and expand advanced diagnostics nationally. Morgans maintains a “buy” rating on Sonic but has slightly adjusted its 12-month target price to $28.64 from $29.33, citing intact fundamentals supported by acquisitions, cost control, and strong liquidity for capital management and M&A.
Healius Faces Margin Headwinds Despite Solid EBITDA
Pathology provider Healius (ASX:HLS) experienced a notable share price drop of 11% after releasing its mixed first-half results. While underlying EBITDA rose by a healthy 13.1% to $122.2 million and revenue increased by 3.8% to $688.1 million, broadly meeting expectations, the company’s underlying EBIT of $7.9 million and a reported net profit after tax loss of $30.4 million disappointed investors. This performance was attributed to ongoing margin pressures within its core pathology business.
Despite these challenges, costs were well-controlled, rising only 1.9%, and labour intensity improved sequentially. Pathology EBIT also returned to positive territory. A bright spot for Healius was its subsidiary Agilex Biolabs, acquired in 2022. Agilex delivered a strong result, with revenues up 16% to $21.8 million, translating to a 65.5% improvement in EBITDA to $4.8 million and a 145.5% increase in EBIT to $2.7 million. The strategic shift towards large molecule and immunobiology work at Agilex is gaining traction.
Management anticipates FY26 EBITDA to be in line with consensus of $273 million, reiterating that revenue and profitability will be weighted towards the second half of the financial year. However, Morgans remains “cautious” on Healius, maintaining a “hold” rating and a 12-month target price of 87 cents, indicating that sustainable earnings leverage is still dependent on second-half execution.
Ansell’s Target Price Lifted Despite Soft Top-Line Growth
Morgans has raised its 12-month target price for Ansell (ASX:ANN) from $34.64 to $35.23 following the release of its first-half FY26 results. Analyst Derek Jellinek described the outcome as “stronger than it first appears,” noting that while organic top-line growth was subdued in challenging market conditions, expanding margins drove profits above expectations.
Revenue came in at US$1,027 million, slightly down and 5% below expectations, with underlying volumes flat to lower after accounting for tariff effects. However, EBIT saw a significant 15% increase to US$147 million, pushing margins to 14.3%, surpassing the consensus of 13.2%. This improvement was driven by cost savings, efficiency gains, and margin enhancements across key segments. Adjusted earnings per share (EPS) jumped 19% to US66.3 cents, exceeding forecasts by approximately 12%.
Operating cash flow surged by 72% to US$92 million, facilitating US$47 million in share buybacks and a 20% higher dividend of US26.6 cents. Jellinek highlighted that tariff-related pricing appears to be effective, and synergies from the acquired KBU business are on track, with APIP savings reaching their US$50 million annualised target.
Despite these positives, FY26 guidance was maintained despite a ~$5 million foreign exchange headwind. The market’s focus now shifts from execution to the sustainability of these improvements, particularly given limited volume growth and the company’s upcoming CEO transition alongside a major ERP rollout, which introduces an element of uncertainty. Morgans maintains a “hold” rating on Ansell.
Telix Pharmaceuticals Delivers Robust Full-Year Performance
Telix Pharmaceuticals (ASX:TLX) saw its share price climb more than 6% after announcing a strong full-year FY25 result. The company reported revenue of US$803.8 million, a significant 56% increase year-on-year, and adjusted EBITDA of US$39.5 million, both broadly in line with market expectations. This growth was primarily fuelled by the success of its prostate cancer imaging product, Illuccix, and the ramp-up of its kidney cancer imaging product, Gozellix. Telix also expanded its manufacturing capabilities to support future expansion.
For FY26, Telix has guided for revenue between US$950–$970 million, positioning it approximately 3–5% above current market forecasts. The Precision Medicine division generated US$621.9 million, up 22%, with a solid 64% gross margin. The Radio-pharmacy Services (RLS) segment contributed US$170.1 million in third-party revenue, delivering positive adjusted EBITDA and enhancing recurring revenue quality. Gross profit increased by 27% to US$426.4 million.
The elevated spending on late-stage cancer therapies and manufacturing scale-up is reflected in the adjusted EBITDA of US$39.5 million. Importantly, several late-stage therapeutic programs targeting prostate, kidney, glioblastoma (GBM), and bone pain made significant progress during the year, de-risking the company’s future treatment pipeline. Morgans healthcare analyst Iain Wilkie noted that Telix’s FY26 revenue guidance exceeds current consensus, driven by continued momentum in precision medicine and a full-year contribution from RLS. The company expects to maintain its mid-20% investment ratio in research and development, with guidance set between US$200–$240 million. Wilkie pointed to several upcoming catalysts, including US regulatory submissions for its brain cancer imaging agent Pixclara and kidney cancer imaging product Zircaix. The consensus target price for Telix stands at $24.11.
CogState Reports Broad-Based Growth Driven by Innovation
Neuroscience technology company CogState (ASX:CGS) experienced a share price increase of approximately 3% after delivering a “strong” first-half result characterized by revenue growth, record sales contracts, and expanding operating leverage. Group revenue rose 12% to US$26.9 million, with clinical trials revenue seeing a 13% uplift.
Net profit after tax (NPAT) increased by 16% to US$4.5 million, while EBITDA grew 5% to US$6.5 million, maintaining a 24% margin that reflects scale benefits despite temporary margin impacts. Clinical Trials contracts saw a substantial 105% increase to US$41.7 million, significantly bolstering future revenue, which now totals US$104.9 million.
CogState has continued to invest in scientific resources, AI-enabled analytics, and channel partnerships. The company enters the second half of FY26 with “strong momentum,” supported by record contracted revenue of US$21.7 million expected for the half and a robust sales pipeline. Management anticipates revenue growth in both the second half of FY26 and into FY27, contingent on new contract conversions. Gross margins are forecast to recover to 56-59% as one-off cost impacts are resolved, with long-term potential exceeding 60%. Operating costs are expected to remain disciplined, enabling continued operational leverage as revenue scales.
Power highlighted CogState’s multiple growth drivers, including strategic partnerships like its collaboration with Medidata to integrate electronic Clinical Outcome Assessment (eCOA) and AI solutions for more efficient trials, with Phase III opportunities anticipated from 2026–2027. The central nervous system (CNS) trial solutions market is projected to reach US$1–1.3 billion by 2030, while the broader eCOA market is expected to expand at a 15% compound annual growth rate. CogState is also advancing AI and automation tools, pursuing global expansion into new therapeutic areas, and scaling rater certification programs to ensure data quality and consistency. FactSet has a consensus target price of $3.08 on CogState.
Reporting Season Continues: Key Companies to Watch
The reporting season is far from over, with a number of significant ASX healthcare stocks due to release their results in the coming week. Among the key names on Morgans’ radar are Australia’s largest healthcare provider, Ramsay Health Care (ASX:RHC), and pharmaceutical distributor and Chemist Warehouse owner, Sigma Healthcare (ASX:SIG). EBOS Group (ASX:EBO), another major pharmaceutical distributor, will also be presenting its half-year results.
Ramsay Health Care’s Strategic Separation: In a significant development, Ramsay Health Care announced its intention to separate its 52.79% stake in European healthcare operator Ramsay Santé. This would be achieved through an in-specie distribution to Ramsay shareholders, subject to necessary approvals, with implementation targeted for the fourth quarter of 2026. This move follows a strategic review and would result in the full deconsolidation of Ramsay Santé from RHC’s financial statements. Additionally, Ramsay confirmed the termination of its shareholder agreement with Prédica, removing structural constraints. Morgans views this proposed separation as strategically sound and sentimentally positive, aligning with management’s simplification agenda and refocus on Australia by removing a lower-margin, capital-intensive European business. Morgans maintains a “hold” rating on Ramsay with a 12-month target price of $35.22.
